Xencor Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, has appointed Bart Cornelissen as senior vice president and chief financial officer.
Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor
Xencor to Present at Upcoming Investor Conferences
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor to Host Webcast to Review Q4 and Full Year 2023 Financial Results
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
Xencor and CytomX Therapeutics have taken a scalpel to their pipelines, stopping work on an ex-AbbVie antibody-drug conjugate (ADC) and pulling back from a co-development deal with Genentech to focus cash on other projects.
Xencor Reports Third Quarter 2023 Financial Results